Valeant Pharmaceuticals International (VRX) Earns Daily News Sentiment Score of 0.18
Media headlines about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Valeant Pharmaceuticals International earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.041045593029 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher? (finance.yahoo.com)
- Golden Stock-:- Valeant Pharmaceuticals International, Inc. (NYSE:VRX) – Market Breaking Point (press release) (journalfinance.net)
- Valeant Stock Surge Draws Fresh Batch of Options Bulls – Schaeffers Research (schaeffersresearch.com)
- Toll Brothers earnings show inflation creeping up everywhere (finance.yahoo.com)
- Forget missing out on bitcoin mania, be glad you didn’t short it (finance.yahoo.com)
Several brokerages have weighed in on VRX. Deutsche Bank set a $18.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research note on Sunday, December 3rd. Vetr upgraded shares of Valeant Pharmaceuticals International from a “buy” rating to a “strong-buy” rating and set a $19.72 price objective for the company in a research note on Tuesday, December 5th. Piper Jaffray Companies reiterated a “sell” rating and issued a $12.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, November 10th. BMO Capital Markets raised their target price on shares of Valeant Pharmaceuticals International from $16.00 to $17.00 and gave the company a “market perform” rating in a report on Monday, November 13th. Finally, HC Wainwright reissued a “hold” rating and issued a $17.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, November 9th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $17.46.
In other news, Director John Paulson purchased 344,216 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the transaction, the director now owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 5.87% of the stock is currently owned by insiders.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.